Table of Contents
Novo Nordisk’s Indian semaglutide patent expired in India on March 20, as Lupin and Sun Pharma disclosed separate semaglutide developments in the market.
Lupin entered a licensing and supply agreement with Zydus Lifesciences on March 17 to co-market Zydus’ semaglutide injection, 15 mg/3 mL, in India.
The agreement gives Lupin semi-exclusive rights to co-market the product under the brand names Semanext and Livarise. Zydus will continue to market the product under the brand names SEMAGLYN, MASHEMA, and ALTERME.
Lupin will pay Zydus upfront licensing fees and milestone payments on achieving pre-defined milestones.
On March 21, Sun Pharma launched semaglutide injections in India, in all strengths, under the brand names Noveltreat and Sematrinity.
Noveltreat is indicated for chronic weight management in adults as an adjunct to a reduced-calorie diet and increased physical activity. Sematrinity is indicated for adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise.
Sun Pharma said the products are priced significantly lower than the innovator brand, with weekly therapy costs ranging from approximately ₹900 to ₹2,000 for Noveltreat and ₹750 to ₹1,300 for Sematrinity. The company cited NFHS-5 data stating that almost one in four Indians aged 15 to 49 is overweight or obese, and ICMR INDIAB 17 study data stating that an estimated 101.3 million people had diabetes in India.
Sources: Sun Pharma, Lupin, BBC
Comments